Neurogene to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following investor conferences:

TD Cowen 44th Annual Health Care Conference
Format: Management will participate in a CNS Corporate Panel and investor meetings
Date: Tuesday, March 5 at 10:30 a.m. ET

Leerink Partners Global Biopharma Conference
Format: Management will participate in investor meetings
Date: Monday, March 11

Stifel 2024 Virtual CNS Days
Format: Management will participate in a fireside chat
Date: Wednesday, March 20 at 9:30 a.m. ET

Live webcasts of the panel and fireside chat can be accessed from the Investor Relations section of Neurogene’s website under events, where a replay of the events will also be available for a limited time.

About Neurogene

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and by designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit www.neurogene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240229815231/en/

Neurogene Contacts:
Investor Relations:
Melissa Forst
Argot Partners
[email protected]

Media:
David Rosen
Argot Partners
[email protected]

Source: Neurogene Inc.

You May Also Be Interested In

• Neurogene (NGNE) PT Lowered to $65 at H.C. Wainwright
• Strategic Investment in Production Expansion: Impact Fusion International (IFUS) Installs Proprietary Machinery to Enhance Production Capacity
• Discover Jordan with Greater Ease: Wego and the Jordan Tourism Board Bring Ahlan Jordan to MENA Travellers